Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial
<p><b>Background</b></p> The purpose of this 6-month intervention pilot feasibility randomised trial was to test sending brief messages using mobile phones to promote self-management through taking medication as prescribed to people with type 2 diabetes. This was to inform th...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Andre forfattere: | |
| Format: | Journal article |
| Sprog: | English |
| Udgivet: |
BioMed Central
2024
|
| _version_ | 1826312099487285248 |
|---|---|
| author | Farmer, AJ Allen, J Bartlett, YK Bower, P Chi, Y French, DP Gudgin, B Holmes, E Horne, R Hughes, DA Jones, L Kenning, C Locock, L McSharry, J Miles, L Newhouse, N Rea, R Robinson, S Tarassenko, L Velardo, C Williams, N Yu, L |
| author2 | SuMMiT-D Collaborative Group |
| author_facet | SuMMiT-D Collaborative Group Farmer, AJ Allen, J Bartlett, YK Bower, P Chi, Y French, DP Gudgin, B Holmes, E Horne, R Hughes, DA Jones, L Kenning, C Locock, L McSharry, J Miles, L Newhouse, N Rea, R Robinson, S Tarassenko, L Velardo, C Williams, N Yu, L |
| author_sort | Farmer, AJ |
| collection | OXFORD |
| description | <p><b>Background</b></p>
The purpose of this 6-month intervention pilot feasibility randomised trial was to test sending brief messages using mobile phones to promote self-management through taking medication as prescribed to people with type 2 diabetes. This was to inform the design and conduct of a future large-scale United Kingdom-based clinical trial and establish the feasibility of recruitment, the technology used, follow-up, and data collection.
<p><b>Methods</b></p>
A multicentre individually randomised, controlled parallel group trial in primary care, recruiting adults (≥ 35 years) with type 2 diabetes in England. Consenting participants were randomly allocated to receive short message system text messages up to four times a week, or usual care, for a period of 6 months; messages contained behavioural change techniques targeting medication use. The primary outcome was the rate of recruitment to randomisation of participants to the trial with a planned rate of 22 participants randomised per month. The study also aimed to establish the feasibility of follow-up at 6 months, with an aim of retaining more than 80% of participants. Data, including patient-reported measures, were collected at baseline and the end of the 6-month follow-up period, and a notes review was completed at 24 months.
<p><b>Results</b></p>
The trial took place between 26 November 2018 and 30 September 2019. In total 209 participants were randomly allocated to intervention (n = 103) or usual care (n = 106). The maximum rate of monthly recruitment to the trial was 60–80 participants per month. In total, 12,734 messages were sent to participants. Of these messages, 47 were identified as having failed to be sent by the service provider. Participants sent 2,864 messages to the automated messaging system. Baseline data from medical records were available for > 90% of participants with the exception of cholesterol (78.9%). At 6 months, a further HbA1c measurement was reported for 67% of participants. In total medical record data were available at 6 months for 207 (99.0%) of participants and completed self-report data were available for 177 (84.7%) of participants.
<p><b>Conclusion</b></p>
The feasibility of a large-scale randomised evaluation of brief message intervention for people with type 2 diabetes appears to be high using this efficient design. Failure rate of sending messages is low, rapid recruitment was achieved among people with type 2 diabetes, clinical data is available on participants from routine medical records and self-report of economic measures was acceptable.
<p><b>Trial registration</b></p>
ISCTRN ISRCTN13404264. Registered on 10 October 2018. |
| first_indexed | 2024-03-07T08:22:31Z |
| format | Journal article |
| id | oxford-uuid:ffb4c0b8-74ab-421b-a50a-9adaa7f2bc54 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:22:31Z |
| publishDate | 2024 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:ffb4c0b8-74ab-421b-a50a-9adaa7f2bc542024-02-01T09:13:39ZSupporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ffb4c0b8-74ab-421b-a50a-9adaa7f2bc54EnglishSymplectic ElementsBioMed Central2024Farmer, AJAllen, JBartlett, YKBower, PChi, YFrench, DPGudgin, BHolmes, EHorne, RHughes, DAJones, LKenning, CLocock, LMcSharry, JMiles, LNewhouse, NRea, RRobinson, STarassenko, LVelardo, CWilliams, NYu, LSuMMiT-D Collaborative Group<p><b>Background</b></p> The purpose of this 6-month intervention pilot feasibility randomised trial was to test sending brief messages using mobile phones to promote self-management through taking medication as prescribed to people with type 2 diabetes. This was to inform the design and conduct of a future large-scale United Kingdom-based clinical trial and establish the feasibility of recruitment, the technology used, follow-up, and data collection. <p><b>Methods</b></p> A multicentre individually randomised, controlled parallel group trial in primary care, recruiting adults (≥ 35 years) with type 2 diabetes in England. Consenting participants were randomly allocated to receive short message system text messages up to four times a week, or usual care, for a period of 6 months; messages contained behavioural change techniques targeting medication use. The primary outcome was the rate of recruitment to randomisation of participants to the trial with a planned rate of 22 participants randomised per month. The study also aimed to establish the feasibility of follow-up at 6 months, with an aim of retaining more than 80% of participants. Data, including patient-reported measures, were collected at baseline and the end of the 6-month follow-up period, and a notes review was completed at 24 months. <p><b>Results</b></p> The trial took place between 26 November 2018 and 30 September 2019. In total 209 participants were randomly allocated to intervention (n = 103) or usual care (n = 106). The maximum rate of monthly recruitment to the trial was 60–80 participants per month. In total, 12,734 messages were sent to participants. Of these messages, 47 were identified as having failed to be sent by the service provider. Participants sent 2,864 messages to the automated messaging system. Baseline data from medical records were available for > 90% of participants with the exception of cholesterol (78.9%). At 6 months, a further HbA1c measurement was reported for 67% of participants. In total medical record data were available at 6 months for 207 (99.0%) of participants and completed self-report data were available for 177 (84.7%) of participants. <p><b>Conclusion</b></p> The feasibility of a large-scale randomised evaluation of brief message intervention for people with type 2 diabetes appears to be high using this efficient design. Failure rate of sending messages is low, rapid recruitment was achieved among people with type 2 diabetes, clinical data is available on participants from routine medical records and self-report of economic measures was acceptable. <p><b>Trial registration</b></p> ISCTRN ISRCTN13404264. Registered on 10 October 2018. |
| spellingShingle | Farmer, AJ Allen, J Bartlett, YK Bower, P Chi, Y French, DP Gudgin, B Holmes, E Horne, R Hughes, DA Jones, L Kenning, C Locock, L McSharry, J Miles, L Newhouse, N Rea, R Robinson, S Tarassenko, L Velardo, C Williams, N Yu, L Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial |
| title | Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial |
| title_full | Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial |
| title_fullStr | Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial |
| title_full_unstemmed | Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial |
| title_short | Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D pilot): results of a feasibility randomised trial |
| title_sort | supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care summit d pilot results of a feasibility randomised trial |
| work_keys_str_mv | AT farmeraj supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT allenj supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT bartlettyk supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT bowerp supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT chiy supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT frenchdp supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT gudginb supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT holmese supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT horner supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT hughesda supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT jonesl supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT kenningc supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT locockl supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT mcsharryj supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT milesl supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT newhousen supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT rear supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT robinsons supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT tarassenkol supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT velardoc supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT williamsn supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial AT yul supportingpeoplewithtype2diabetesineffectiveuseoftheirmedicinethroughmobilehealthtechnologyintegratedwithclinicalcaresummitdpilotresultsofafeasibilityrandomisedtrial |